News AZ takes Medicare negotiation appeal to SCOTUS AstraZeneca has elevated its challenge to Medicare drug price negotiation powers to the Supreme Court of the US.
News AZ's bid for Fasenra approval in COPD falls short AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.
News Imfinzi becomes first NHS drug for aggressive lung cancer AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.
News AZ halts UK investment, and Lilly, Sanofi follow suit After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.
News Mixed data from lung cancer trials on show at WCLC Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.
News ESC: 'Landmark' study backs AZ's baxdrostat for hypertension The race to market is on with Mineralys, as AstraZeneca showcases data for aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
